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Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in early
phase studies in advanced/metastatic gastric/gastroesophageal junction cancer, including as first-line
maintenance therapy. Here, we describe the design of JAVELIN Gastric 100 (NCT02625610), an open-label,
Phase III trial. A total of 499 patients with locally advanced/metastatic HER2- gastric/gastroesophageal
junction cancer adenocarcinoma, who had achieved at least stable disease following 12 weeks of first-line
oxaliplatin/fluoropyrimidine chemotherapy, have been randomized 1:1 to receive avelumabmaintenance
therapy or continue chemotherapy. The primary objective is to demonstrate superior overall survival in all
randomized patients or in the PD-L1+ population. Secondary objectives are to demonstrate superiority
for progression-free survival and objective response rate, compare quality of life measures, and determine
safety.
First draft submitted: 30 August 2018; Accepted for publication: 12 October 2018; Published online:
31 October 2018
Keywords: avelumab • gastric cancer • PD-L1
Future Oncol. (2019) 15(6), 567–577 ISSN 1479-6694 56710.2217/fon-2018-0668 C© 2018 Markus Moehler
Clinical Trial Protocol Moehler, Ryu, Dvorkin et al.
Palliative/BSC
Karnofsky PS
<60% or
ECOG PS ≥3
Karnofsky PS
≥60% or
ECOG PS ≤2
Performance
status
Preferred 1L
treatment options*†
Preferred 2L or
later treatment options
Other 1L regimens Other 2L regimens
Locally
advanced or
metastatic
disease
Disease
characteristics
Fluoropyrimidine (fluorouracil‡
or capecitabine) + cisplatin
•
Fluoropyrimidine (fluorouracil‡
or capecitabine) + oxaliplatin
•
Fluorouracil‡ + irinotecan•
Modified DCF•
ECF or modified ECF•
S-1 + cisplatin§•
Trastuzumab (+ 1L chemotherapy)¶•
Ramucirumab + paclitaxel•
Docetaxel•
Paclitaxel•
Irinotecan•
Ramucirumab•
Fluorouracil + irinotecan#•
Paclitaxel + cisplatin
or carboplatin
•
Docetaxel + cisplatin•
Fluoropyrimidine‡•
Docetaxel•
Paclitaxel•
Irinotecan and cisplatin•
Pembrolizumab
-  MSI-H or dMMR tumors
-  3L or later therapy for
   PD-L1+ GC/GEJC
•
Docetaxel and irinotecan or later•
Nivolumab
-  Approved in Japan for advanced
   or recurrent disease that has
   progressed on chemotherapy
•
Figure 1. Treatment landscape in advanced gastric/gastroesophageal junction cancer based on National Comprehensive Cancer
Network, European Society for Medical Oncology and Japanese guidelines, and recent approvals.
*Participation in clinical trials of new or more tolerable therapy is recommended.
†Doublet cytotoxic regimens are preferred because of lower toxicity. Triplet cytotoxic regimens should be reserved for medically fit
patients with good PS and access to frequent toxicity evaluation.
‡Leucovorin is indicated with certain fluorouracil-based regimens.
§Standard-of-care recommendation for 1L treatment based on Japanese GC treatment guidelines.
¶For HER2-overexpressing advanced disease.
#Capecitabine may not be used interchangeably with fluorouracil in regimens containing irinotecan and is only recommended if not
previously used in 1L.
1L: First line; 2L: Second line; 3L: Third line; BSC: Best supportive care; DCF: Docetaxel + cisplatin + fluorouracil (substitutions for cisplatin
include oxaliplatin or carboplatin); dMMR: Mismatch repair deficient; ECF: Epirubicin, cisplatin and fluorouracil (substitution for cisplatin
include use of oxaliplatin, cisplatin or capecitabine); ECOG: Eastern Cooperative Oncology Group; ESMO: European Society for Medical
Oncology; GC: Gastric cancer; GEJC: Gastroesophageal junction cancer; MSI-H: Microsatellite instability-high; NCCN: National
Comprehensive Cancer Network; PS: Performance status.
Gastric cancer (GC), the fifth most common cancer and the third leading cause of cancer-related death worldwide,
presents a considerable global health burden [1]. Although the incidence of GC is decreasing, the most recent
estimates indicate that approximately 1 million individuals are diagnosed with GC each year, of whom half are
from Asia [1]. In the western hemisphere, most patients with GC are diagnosed at an advanced stage and face a poor
prognosis [2], whereas enhanced screening programs in Asia have led to more frequent diagnosis at early stages [3].
Gastroesophageal junction cancer (GEJC) is a distinct cancer from GC, although evidence suggests that GEJC has
a similar biology to that of GC, and recommended treatments are similar for both tumor types, particularly in the
metastatic setting [4,5].
Systemic chemotherapy is the standard treatment for advanced GC/GEJC [2], and first-line (1L) treatment
selection is generally based on patient performance status (PS) and tumor HER2 expression (Figure 1) [3,5–7].
Recommended standard of care for patients with HER2- tumors typically involves doublet cytotoxic regimens
including a platinum agent and a fluoropyrimidine [3,5,6]. Triplet cytotoxic regimens, which are less well toler-
ated [8] are generally reserved for fit patients with a good PS [5], although better-tolerated triplet regimens are
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being assessed [9]. For patients with HER2+ tumors, trastuzumab (an anti-HER2 antibody) in combination with
cisplatin-based chemotherapy is the standard treatment [5,10]. Despite improvements in chemotherapy for patients
with advanced GC/GEJC, the median overall survival (OS) remains short, ranging from 8 to 15 months with
standard 1L chemotherapy, 4–9 months with second-line (2L) regimens, and 3–5 months with third-line (3L)
treatment [5,11,12].
Because patients with advanced GC/GEJC often have poor prognostic factors that limit long-term use of
standard combination chemotherapy regimens [3,5,13], an optimal continuum of care, during which all available
treatment options are administered to maximize the overall benefit across all lines of treatment, is needed. One
strategy that could improve and extend the duration of tumor responses/disease control, progression-free survival
(PFS), OS and quality of life (QOL) in the 1L setting without additive toxicity is maintenance treatment, which
may involve continuation or de-escalation of 1L chemotherapy, or sequential treatment with a different agent in
patients with nonprogressive disease (switch maintenance) [14–17]. In patients with non-small-cell lung cancer and
colorectal cancer, who have a poor prognosis similar to that of advanced GC/GEJC, maintenance treatment has
been shown to extend the duration of antitumor benefit following standard 1L induction treatment [14–17]. Fur-
thermore, reintroduction of the 1L chemotherapy regimen following disease progression on (switch) maintenance
treatment is also possible [18]. Although maintenance treatment for advanced GC/GEJC has not been studied
extensively, observational and retrospective studies reported to date have shown that maintenance treatment with
fluoropyrimidines is feasible and may improve PFS compared with observation [19–21]. Moreover, trastuzumab or
ramucirumab are administered continuously until disease progression in patients with GC/GEJC [5], suggesting
that evaluation of long-term treatment with other agents is warranted.
Because GC/GEJC is associated with immune system evasion, immunotherapy targeting immunological check-
point proteins, such as PD-1 and its ligand, PD-L1, which aims to restore immune responses in GC/GEJC, is a
rational approach [22–24]. Consistent with this, anti-PD-1 antibodies have shown encouraging efficacy and safety
profiles in patients with advanced GC/GEJC [25–28]. In addition, chemotherapy has well-documented immuno-
genic effects [29], and early clinical trials in various tumor types have shown that combination treatment with
immunotherapy and chemotherapy may increase the frequency of antitumor responses compared with chemother-
apy alone [29], including in GC/GEJC [26]. The first study to assess whether maintenance immunotherapy could
leverage the immunogenic effects of chemotherapy was a recent randomized, Phase II, proof-of-concept trial of
maintenance treatment with the anti-CTLA4 antibody ipilimumab after platinum/fluoropyrimidine-based induc-
tion chemotherapy in patients with advanced GC/GEJC [30]. Although no significant benefit in median PFS or OS
was seen with ipilimumab compared with best supportive care, which included ongoing fluoropyrimidine treatment
in approximately 80% of patients, full interpretation was limited by a relatively short duration of follow-up [30],
and the mechanism of action of ipilimumab may not be optimal in the maintenance setting.
Avelumab
Avelumab (Bavencio R©) is a human anti-PD-L1 IgG1 antibody that binds PD-L1 and inhibits its interaction with
PD-1 [31]. Avelumab has shown encouraging efficacy and acceptable safety in patients with various tumors and
has received regulatory approval in various countries for the treatment of metastatic Merkel cell carcinoma and in
the USA and Canada for advanced urothelial carcinoma that has progressed during or after platinum-containing
chemotherapy [32–35]. Two Phase I studies, JAVELIN Solid Tumor (NCT01772004) and JAVELIN Solid Tumor
JPN (NCT01943461), have shown that avelumab treatment has an acceptable safety profile and is associated
with promising rates of objective response and disease stabilization in patients with advanced GC/GEJC [36,37]. In
particular, in the JAVELIN Solid Tumor trial, avelumab was administered to a large Phase IB cohort of 150 patients
with locally advanced or metastatic GC/GEJC, who were recruited to two subgroups according to whether or not
they had disease progression after 1L chemotherapy (i.e., avelumab was administered either as 2L therapy after
disease progression or as 1L maintenance therapy in patients who had achieved at least stable disease [SD]) [36].
The overall response rate (ORR) with avelumab treatment was 6.7% in both subgroups, but a complete response
(CR) was achieved in 2.2% of patients who received avelumab as 1L maintenance treatment. Median OS in the
1L maintenance and 2L subgroups was 11.1 and 6.6 months, respectively, and in the 1L maintenance subgroup,
median OSmeasured from start of 1L chemotherapy was 18.7 months. The safety profile of avelumab was generally
consistent with that of other anti-PD-L1/PD-1 antibodies and did not overlap with the relatively severe toxicities
seen with cytotoxic chemotherapy regimens. Overall, the efficacy and safety of avelumab in the 1L maintenance
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setting seen in the JAVELIN Solid Tumor trial are highly encouraging and warrant evaluation in a larger randomized
trial.
JAVELIN Gastric 100 trial
We describe the design of the randomized, open-label, Phase III trial JAVELIN Gastric 100 (NCT02625610)
comparing maintenance avelumab with continuation of 1L chemotherapy in patients with advanced GC/GEJC.
Objectives
The primary objective of this trial is to demonstrate that avelumab maintenance therapy is superior to continuation
of 1L chemotherapy with regard to OS measured from randomization, that is, the start of maintenance treatment,
in all randomized patients or in patients with PD-L1+ tumors. Secondary objectives are to demonstrate superior
PFS and ORR with avelumab versus continuation of 1L chemotherapy (according to Response Evaluation Criteria
in Solid Tumors v1.1 and as per investigator assessment, with baseline defined as the last measurement performed
prior to randomization), to evaluate the safety and tolerability of avelumab, and to assess patient-reported outcomes
(PROs) and QOLmeasures with avelumab versus continuation of 1L chemotherapy. Exploratory objectives include
evaluation of target lesion reduction from baseline during the maintenance phase; exploration of the molecular,
cellular and soluble markers relevant to the mechanism of action of avelumab and the response or resistance
to treatment, including PD-L1 expression in tumor cells and immune infiltrates; assessment of the duration of
and time to response with avelumab; and characterization of the pharmacokinetic profile and immunogenicity of
avelumab.
Key eligibility criteria
All patients must be aged ≥18 years and have histologically confirmed, previously untreated, unresectable, locally
advanced or metastatic HER2- GC/GEJC measurable by Response Evaluation Criteria in Solid Tumors v1.1.
Other inclusion criteria are: Eastern Cooperative Oncology Group PS score of 0–1; availability of a formalin-
fixed, paraffin-embedded block containing tumor tissue or unstained tumor slides suitable for PD-L1 expression
assessment; estimated life expectancy of ≥12 weeks; adequate renal, hepatic and hematologic function; no major
surgery within 4 weeks of enrollment (other than diagnostic biopsy); and no vaccination within 55 days of the first
dose of avelumab (with exception for inactivated vaccines). Patients are not permitted to have received any prior
chemotherapy for advanced/metastatic disease or any prior therapy with a drug targeting a T-cell co-regulatory
protein, and are not permitted to receive concurrent treatment with anticancer or immunosuppressive agents.
Additionally, enrolled patients must have no evidence of CNS metastases or malignant disease other than GC
within the previous 5 years and no history of uncontrolled or clinically significant illness, including prior organ
transplant, infection, autoimmune disease and cardiovascular disease. Finally, patients must have no history of
allergy to monoclonal antibodies, no history of anaphylaxis, and no uncontrolled asthma.
Study design
JAVELIN Gastric 100 is a randomized, open-label, global, multicenter, Phase III trial. Enrollment began in
December 2015 and is now complete. Patients were recruited at 200 sites in North America, South America,
Asia–Pacific and Europe. All recruited patients received 1L therapy with oxaliplatin, leucovorin and 5-fluorouracil
(FOLFOX/FLO) or oxaliplatin and capecitabine (XELOX/CAPOX) for 12 weeks (Figure 2). Following this in-
duction phase, patients were reassessed for eligibility, and 499 patients with a CR, partial response or SD were ran-
domized 1:1 to receive maintenance therapy with either avelumab 10 mg/kg administered by intravenous infusion
every 2 weeks or continuation of the same chemotherapy regimen from the induction phase. Patients randomized to
the nonavelumab arm deemed ineligible to receive further chemotherapy receive best supportive care alone. Patients
randomized to receive avelumab must be premedicated with an antihistamine and paracetamol/acetaminophen
(modified based on local treatment standards and guidelines as appropriate) 30–60 min prior to the first four
infusions. Maintenance treatment is given until confirmed disease progression, significant clinical deterioration,
unacceptable toxicity or other protocol-specified criteria for discontinuation occur. The primary end point of the
trial is OS. Secondary end points include PFS, best overall response, PROs/QOL measures, safety and tumor
biomarkers.
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Figure 2. Gastric 100 trial design.
1L: First line; BOR: Best overall response; BSC: Best supportive care; CAPOX: Capecitabine and oxaliplatin; FOLFOX: Oxaliplatin, leucovorin
and fluorouracil; GC: Gastric cancer; GEJC: Gastroesophageal junction cancer; OS: Overall survival; PFS: Progression-free survival; PRO:
Patient-reported outcome; Q2W: Every 2 weeks; QOL: Quality of life; R: Randomization.
Evaluations
Antitumor responses are assessed via computed tomography or MRI every 6 weeks for the first 12 months after
randomization and every 12 weeks thereafter. Safety is assessed throughout and is graded based on National
Cancer Institute Common Terminology Criteria for Adverse Events v4.03. Treatment-related adverse events are
monitored for 30 (±5) days following the end of protocol treatment. Potential immune-related adverse events
that may result from avelumab treatment are considered adverse events of special interest. Blood samples are
collected to analyze the pharmacokinetic profile and immunogenicity of avelumab. PROs and QOL are assessed
using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EuroQoL EQ-
5D-5 L and EORTC Gastric Cancer Module QLQ-STO22 questionnaires. PD-L1 expression in tumor cells
and/or cells in the tumor microenvironment (nonmalignant tumor-infiltrating cells and stromal cells) will be
assessed retrospectively using the PD-L1 IHC 73-10 assay (Dako, CA, USA; under license of Merck KGaA), an
investigational immunohistochemistry assay developed for the Dako Autostainer Link 48 platform, which uses
the 73-10 anti-PD-L1 monoclonal antibody clone. PD-L1 expression will be scored based on the percentage of
PD-L1+ cells and the intensity of staining. Other predictive biomarker assessments are also planned.
Statistical analysis methods
Efficacy end points are analyzed in all randomized patients on an intent-to-treat basis. The primary analysis
population for all analyses of efficacy and safety consists of all patients who have an overall tumor response status
of CR, partial response or SD after completing the induction phase and who are subsequently randomized to
trial treatment. The sample size of this trial is driven by the primary end point of OS, which is defined as the
time from randomization to the date of death due to any cause. This trial has two primary hypotheses, which
are that avelumab is superior to 1L chemotherapy in terms of OS in all randomized patients and in the PD-L1+
population. Superiority will be tested with a hierarchical strategy that preserves the type 1 error rate at 2.5% (one
sided). The study will be considered positive if at least one of the primary hypotheses is statistically significant in
either of the populations. OS will be summarized using the Kaplan–Meier method, and 95% CIs for the medians
will be calculated using the two-sided Brookmeyer and Crowley method. Based on a hierarchical testing strategy,
PFS and best overall response will be tested at the primary analysis only if both OS hypotheses (superiority in all
randomized patients and in PD-L1+ patients) reach statistical significance. All safety and QOL measures will be
assessed using descriptive statistics by treatment arm.
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Ethical considerations
The JAVELIN Gastric 100 trial is being conducted in compliance with the protocol, in accordance with the ethical
principles put forward in the second Declaration of Helsinki, and in accordance with good clinical practice rules.
All patients provided written informed consent.
Discussion & future perspective
Across several studies, anti-PD-L1/PD-1 antibodies have shown clinical activity and durability of response in
pretreated patients with advanced GC/GEJC and disease progression following chemotherapy [25–28,36–38], leading
to regulatory approval of nivolumab in Japan for patients with advanced GC progressed after chemotherapy (based
on a Phase III trial vs placebo) [27,39], and accelerated approval of pembrolizumab in the USA as 3L treatment for
advanced PD-L1+ GC/GEJC (based on a large, Phase I, single-arm cohort) [26,40]. However, it has recently been
reported that two randomized, Phase III trials of later-line treatment for GC/GEJC did not show superior OS with
an anti-PD-1 or anti-PD-L1 antibody when compared directly with chemotherapy; this includes KEYNOTE-061
(NCT02370498), a trial of 2L pembrolizumab versus paclitaxel [41], and JAVELINGastric 300 (NCT02625623), a
trial of 3L avelumab versus physician’s choice of chemotherapy [42]. These findings indicate that anti-PD-L1/PD-1
monotherapy is not superior to chemotherapy in patients with disease progression on prior chemotherapy, increasing
the interest in Phase III trials of GC/GEJC assessing alternative immunotherapy-based strategies incorporating
sequential or combination chemotherapy.
Anti-PD-1 agents have shown encouraging results in early phase trials when administered as monotherapy or in
combination with chemotherapy for 1L treatment of advanced GC/GEJC. In this setting, standard chemotherapy
is associated with response rates of 17–52% [5]. In two cohorts of patients with GC/GEJC enrolled in the
KEYNOTE-059 study, the ORR with 1L pembrolizumab combined with 5-fluorouracil and cisplatin was 60%
and with 1L pembrolizumab monotherapy (patients with PD-L1+ tumors only) was 26% [43]. In addition, interim
analyses from ATTRACTION-04, an ongoing Phase II/III trial assessing combination treatment with nivolumab
and chemotherapy as 1L treatment for advanced GC/GEJC, showed ORRs of 67 and 71% in patients treated with
nivolumab plus either S-1 plus oxaliplatin or capecitabine and oxaliplatin [44].
Maintenance treatment with anti-PD-L1/PD-1 antibodies after 1L induction chemotherapy may provide an
alternative treatment strategy to 1L combination treatment, with the aim of enabling patients with advanced
GC/GEJC to obtain the efficacy benefits of checkpoint inhibitor therapy without the increased toxicity burden
of combination treatment. This treatment strategy might also better preserve patient QOL and enable a longer
duration of treatment benefit. To date, JAVELIN Gastric 100 is the only Phase III trial evaluating checkpoint
inhibitor maintenance treatment in advanced GC/GEJC, and results from this trial will determine whether
avelumab monotherapy as maintenance treatment has the potential to improve OS in all randomized patients or in
PD-L1+ patients, achieve a more tolerable safety profile and improve patient QOL compared with continuation
of 1L chemotherapy. Durvalumab, an engineered human IgG1 anti-PD-L1 antibody, is also being tested in the
maintenance setting in an ongoing Phase II study (PLATFORM; NCT02678182), although data have not yet
been reported.
The ideal strategy for incorporating immunotherapy in the continuum of care for patients with advanced
GC/GEJC remains to be defined. The JAVELIN Gastric 100 trial of avelumab, along with Phase III trials of
other agents in different lines/populations, will provide further information on the role of anti-PD-L1/PD-1
therapies in the treatment landscape for GC/GEJC. It is possible that in the future, physicians may tailor treatment
strategies based on efficacy, toxicity, QOL considerations and potential impact on subsequent treatment options.
This could include the choice of administering anti-PD-1 or anti-PD-L1 therapy in the 1L setting as monotherapy,
maintenance therapy or in combination with chemotherapy or another immunotherapy. Furthermore, in patients
with disease progression following immunotherapy-containing maintenance regimens for GC/GEJC, it may be
possible to reintroduce previously administered chemotherapy. Results from the JAVELIN Gastric 100 trial and
other ongoing Phase III trials are eagerly awaited to help define future treatment for patients with advanced
GC/GEJC.
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Executive summary
Background
• Combination cytotoxic chemotherapy is the foundation of first-line (1L) treatment for patients with advanced
gastric/gastroesophageal junction cancer (GC/GEJC), although prognosis with standard regimens remains poor.
• Immunotherapy targeting the PD-1/PD-L1 interaction has been associated with clinical activity in patients with
GC/GEJC, but its optimal role within the continuum of care remains unclear.
• Maintenance therapy is an established strategy for treatment of various advanced tumors based on studies
showing prolonged antitumor responses and extended remissions.
• No randomized studies reported to date have evaluated maintenance treatment for patients with advanced
GC/GEJC.
Avelumab
• Avelumab is a human IgG1 anti-PD-L1 monoclonal antibody that has shown durable clinical activity in a range of
tumors, and is approved in various countries worldwide for the treatment of metastatic Merkel cell carcinoma
and in the USA and Canada for advanced urothelial carcinoma that has progressed during or after
platinum-containing chemotherapy.
• In a Phase IB cohort, which enrolled 150 patients with advanced or metastatic GC/GEJC in two subgroups who
received avelumab as 1L maintenance or second-line therapy, avelumab was well tolerated and showed
promising clinical activity; in particular, in the 1L maintenance subgroup, the overall response rate was 6.7%
(complete response in 2.2%), and median OS was 11.1 months measured from the start of avelumab therapy and
18.7 months measured from start of 1L chemotherapy.
JAVELIN Gastric 100 trial
• JAVELIN Gastric 100 is a randomized, open-label, Phase III trial.
• Eligible patients have unresectable, measurable, locally advanced or metastatic HER2- GC/GEJC adenocarcinoma
without prior treatment for advanced disease and are not preselected based on PD-L1 expression.
• Following 12 weeks of 1L oxaliplatin/fluoropyrimidine chemotherapy, 499 patients achieving stable disease,
partial response or complete response were randomized 1:1 to receive maintenance therapy with either
avelumab or continuation of the same 1L chemotherapy regimen until disease progression, unacceptable toxicity
or withdrawal.
• The primary end point is OS, assessed in all randomized patients and in those with PD-L1+ tumors.
• This study will reveal potential treatment strategies for patients with advanced GC/GEJC by providing the first
evaluation of anti-PD-L1 maintenance therapy in this setting.
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